Dutasteride Should NOT Be Used in Patients with Established Prostate Cancer
Dutasteride is contraindicated for prostate cancer treatment and is explicitly not approved for prostate cancer prevention. 1 The FDA label clearly states under "Limitations of Use" that dutasteride capsules are not approved for the prevention of prostate cancer, and critically, the drug carries a black box concern regarding increased risk of high-grade (Gleason 8-10) prostate cancer. 1
Key Evidence Against Use in Prostate Cancer
Increased High-Grade Cancer Risk
The REDUCE trial demonstrated a concerning signal: dutasteride was associated with a higher incidence of Gleason score 8-10 prostate cancer (1% vs 0.5% in placebo) among men aged 50-75 years with prior negative biopsies. 1, 2 This finding mirrors similar results from the finasteride PCPT trial, where high-grade cancers increased from 22.2% to 37% in the treatment arm. 3
Clinical Guidelines Position
The 2009 ASCO/AUA joint clinical practice guideline addresses this exact scenario: men already taking 5-ARIs (like dutasteride) for other indications should be counseled about the observed increase in high-grade prostate cancers. 3 The guideline emphasizes that while some reassurance exists that this may be a detection artifact rather than true biological aggression, the theoretical possibility of increased prostate cancer mortality must be discussed.
Limited Evidence in Active Disease
Castration-Resistant Prostate Cancer
In men with established castration-resistant prostate cancer (CRPC), dutasteride shows minimal efficacy:
- A Phase II study of 28 men with CRPC treated with high-dose dutasteride (3.5 mg daily) showed only 2 partial responses (8%) and median time to progression of just 1.87 months. 4
- While one small retrospective study suggested 17% PSA response rate in CRPC patients, 5 this represents weak evidence and does not support routine use.
Active Surveillance Context
The only potentially favorable data comes from the REDEEM trial in men on active surveillance (not established cancer requiring treatment): dutasteride reduced progression risk by 38% (HR 0.62). 6 However, this represents a very specific population—men with low-risk disease choosing observation—not patients with diagnosed prostate cancer requiring intervention.
Critical Safety Concerns
PSA Monitoring Complications
Dutasteride reduces PSA by approximately 50% within 3-6 months, which significantly complicates cancer surveillance. 1 In men with established prostate cancer, this PSA suppression could mask disease progression. The FDA label explicitly warns that dutasteride may cause PSA decreases even in the presence of prostate cancer, requiring PSA values to be doubled for interpretation after 3+ months of treatment.
MRI Detection Issues
Recent evidence shows dutasteride increases tumor ADC values and reduces lesion conspicuity on multiparametric MRI, potentially making cancers less visible on imaging. 7 This is particularly problematic for monitoring known disease.
Clinical Bottom Line
For patients with established prostate cancer:
- Dutasteride is NOT indicated and should be discontinued
- The drug may mask progression through PSA suppression
- Increased high-grade cancer risk from prevention trials raises safety concerns
- Minimal therapeutic benefit demonstrated in CRPC
For patients on active surveillance with low-risk disease:
- Dutasteride may have a role as adjunctive therapy 6
- This requires careful discussion of risks/benefits
- Close monitoring with adjusted PSA interpretation is mandatory
For patients taking dutasteride for BPH who develop prostate cancer:
- Discontinue dutasteride upon cancer diagnosis
- Establish new PSA baseline after drug washout
- Proceed with standard cancer treatment protocols
The evidence consistently demonstrates that dutasteride has no established role in treating diagnosed prostate cancer and carries potential harms through detection interference and possible promotion of aggressive disease phenotypes.